European launch of major AL amyloidosis registry aims to unlock disease mysteries

NCT ID NCT06205953

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is creating a large European registry of 400 newly diagnosed AL amyloidosis patients. Researchers will collect medical data and blood samples to study the disease using advanced technology. The goal is to better understand how AL amyloidosis develops and progresses, which could lead to improved diagnosis and treatment in the future. Participants must be at least 18 years old, newly diagnosed, and willing to provide samples and follow-up information.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AL amyloidosis Immunoglobulin Light-chain Amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fondazione IRCCS Policlinico San Matteo, Pavia, Viale Golgi 19, 27100

    RECRUITING

    Pavia, Italy

  • Instituto de Investigación Sanitaria de Navarra (IdiSNA) C. de Irunlarrea, 3, 31008 Pamplona, Navarra

    RECRUITING

    Pamplona, Spain

  • Medical Department, Amyloidosis Center, University Hospital, Im Neuenheimer Feld 672

    RECRUITING

    Heidelberg, Germany

  • UMC Utrecht, dept Hematology, Amyloid Expertise Center, Utrecht, Heidelberglaan

    RECRUITING

    Utrecht, Netherlands

  • Universidad de la Republica Hospital de Clinicas "Dr Manuel Quintela"

    RECRUITING

    Montevideo, Uruguay

  • University of Applied Sciences and Arts Northwestern Switzerland, Institute of Medical Engineering and Medical Informatics

    ACTIVE_NOT_RECRUITING

    Muttenz, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.